Studies have shown that active fund managers routinely underperform the S&P500 index*​

Arcus Biosciences, Inc. (NYSE: RCUS)

RCUS Stock Predictions and Ratings

WSX Rating:
STRONG BUY
WSX Forecast (1yr):
38.20%
Analyst Rating:
BUY
Analyst Forecast (1yr):
18.60%

RCUS Stock Analysis

RCUS PE Ratio:

RCUS PEG Ratio: Not Available

RCUS Forward EPS Growth (12 month): 0.00%

RCUS PS Ratio: 10.2

RCUS PSG Ratio: 0.2

RCUS Forward Revenue Growth (12 month): 47.90%

RCUS Articles

No data was found